Colorectal cancer surveillance: What's new and what's next?

Table 3 Summary of United States and European colorectal cancer surveillance guidelines

	ASCO[33]2005	ASCRS[34,35]2005	NCCN[36,37]2014	Denmark[38] 2009	Norway[39]2012	United Kingdom[40]2010
Stage	II-III	I-III	I-III	II-III	II-III	I-III
History and physical	q3-6 mo × 3 yr; q 6 mo in year 4-5	At least q4 mo × 2 yr	q3-6 mo × 2 yr; q6 mo in year 3-5	At 1 mo	q6 mo × 3 yr, q12 mo in year 4-5	None
CEA	q3 mo × at least 3 yr	At least q4 mo × 2 yr	q3-6 mo × 2 yr; q6 mo in year 3-5	At 1, 12 and 36 mo	q6 mo × 3 yr, q12 mo in year 4-5	None
CT chest	Annually × 3 yr if high risk	None	Annually up to 5 yr if high risk	At 12 and 36 mo	Annually × 5 yr	None
CT abdomen/ pelvis	Annually × 3 yr if high risk	None	Annually up to 5 yr if high risk	At 12 and 36 mo	At 6 mo and 5 yr	Once within first 2 yr
CEUS liver	None	None	None	None	At 12, 18, 24, 30, 36 and 48 mo	None
Colonoscopy	At 3 yr and q5 thereafter	q3 yr	At 1 and 4 yr, then q5 yr	None	At 5 yr;or CT colonography at 5 yr	q5 yr

NCCN: National Comprehensive Cancer Network; ASCO: American Society of Clinical Oncology; ASCRS: American Society of Colon and Rectal Cancer Surgeons; UK: United Kingdom 2010 guidelines; Nor: Norwegian 2012 guidelines; CEUS: Contrast-enhanced ultrasound; CEA: Carcinoembryonic antigen; CT: Computed tomography.